Case of Refractory Classic Hodgkin Lymphoma With a Germline Pathogenic Monoallelic Variant in the TNFRSF13B Gene

Mónica Camacho-Arias^{1

2}, Juan Larraz³, Laura Martín-López^{1

2}, Marta Pilar Osuna-Marco^{1

2}, Sara Álvarez de Andrés⁴, Isabel Plaza de Las Heras⁵, Rosa Alonso Gutiérrez⁶, Blanca López-Ibor^{1

2}, Marta Villa^{1

2}

Affiliations

¹ Pediatric Oncology Unit, HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Montepríncipe, HM Hospitales, Madrid, Spain.
² Instituto de Investigación Sanitaria HM Hospitales, Madrid, Spain.
³ University of Glasgow, Glasgow, Scotland.
⁴ Genetics, ABACID Company, Madrid, Spain.
⁵ Department of Nuclear Medicine, HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.
⁶ Department of Radiation Oncology, HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain.

Mónica Camacho-Arias et al. Pediatr Blood Cancer. 2025 Mar.

. 2025 Mar;72(3):e31505.

doi: 10.1002/pbc.31505. Epub 2024 Dec 26.

¹ Pediatric Oncology Unit, HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Montepríncipe, HM Hospitales, Madrid, Spain.
² Instituto de Investigación Sanitaria HM Hospitales, Madrid, Spain.
³ University of Glasgow, Glasgow, Scotland.
⁴ Genetics, ABACID Company, Madrid, Spain.
⁵ Department of Nuclear Medicine, HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.
⁶ Department of Radiation Oncology, HM CIOCC MADRID (Centro Integral Oncológico Clara Campal), Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain.

No abstract available

References

1. S. M. Ansell, “Hodgkin Lymphoma: Diagnosis and Treatment,” Mayo Clinic Proceedings 90, no. 11 (2015): 1574–1583.
1. M. A. Weniger and R. Kuppers, “Molecular Biology of Hodgkin Lymphoma,” Leukemia 35, no. 4 (2021): 968–981.
1. A. J. Moskowitz, G. Shah, H. Schoder, et al., “Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second‐Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma,” Journal of Clinical Oncology 39, no. 28 (2021): 3109–3117.
1. U. Salzer, C. Bacchelli, S. Buckridge, et al., “Relevance of Biallelic Versus Monoallelic TNFRSF13B Mutations in Distinguishing Disease‐Causing From Risk‐Increasing TNFRSF13B Variants in Antibody Deficiency Syndromes,” Blood 113, no. 9 (2009): 1967–1976.
1. A. J. Fried, I. Rauter, S. R. Dillon, H. H. Jabara, and R. S. Geha, “Functional Analysis of Transmembrane Activator and Calcium‐Modulating Cyclophilin Ligand Interactor (TACI) Mutations Associated With Common Variable Immunodeficiency,” Journal of Allergy and Clinical Immunology 128, no. 1 (2011): 226–228.e1.